Engineered Liver Platforms for Different Phases of Drug Development

Trends in Biotechnology

Volumn 35, Issue 2, 2017, Pages 172-183

  Ware, Brenton R ^a,b   Khetani, Salman R ^b  

^a Engineering Research Center and Hydraulics Laboratory   (United States)

^b University of Illinois at Chicago   (United States)

Author keywords

drug induced liver injury; liver on a chip; microfabrication; micropatterned co cultures; primary human hepatocytes

Indexed keywords

CELL CULTURE; DISEASES; METABOLISM; MICROANALYSIS; MICROFABRICATION; PHYSIOLOGY; STEM CELLS;

CELL-CELL INTERACTION; CELLULAR MICROARRAYS; CELLULAR MICROENVIRONMENT; CO-CULTURES; HUMAN LIVER CELLS; HUMAN LIVER MODEL; LIVER INJURIES; PRIMARY HUMAN HEPATOCYTES;

THROUGHPUT;

CLINICAL TRIAL (TOPIC); COCULTURE; DRUG DEVELOPMENT; GASTROINTESTINAL TRACT; HUMAN; LIVER; LIVER PERFUSION; MICROCHIP ANALYSIS; NONHUMAN; ORGAN; PHARMACOKINETICS; PHYSIOLOGY; PRIORITY JOURNAL; REVIEW; TISSUE ENGINEERING; ANIMAL; ARTIFICIAL LIVER; DEVICES; DRUG EFFECTS; EQUIPMENT DESIGN; ORGAN CULTURE TECHNIQUE; PRECLINICAL STUDY; PROCEDURES; TISSUE SCAFFOLD;

ANIMALS; DRUG EVALUATION, PRECLINICAL; EQUIPMENT DESIGN; HUMANS; LIVER; LIVER, ARTIFICIAL; ORGAN CULTURE TECHNIQUES; TISSUE ENGINEERING; TISSUE SCAFFOLDS;

EID: 84994493289     PISSN: 01677799     EISSN: 18793096     Source Type: Journal    
DOI: 10.1016/j.tibtech.2016.08.001     Document Type: Review

References (75)

1. 1 Kaitin, K.I., Deconstructing the drug development process: the new face of innovation. Clin. Pharmacol. Ther. 87 (2010), 356–361.
2. 2 Mullard, A., The phenotypic screening pendulum swings. Nat. Rev. Drug Discov. 14 (2015), 807–809.
3. 3 Kola, I., Landis, J., Can the pharmaceutical industry reduce attrition rates?. Nat. Rev. Drug Discov. 3 (2004), 711–715.
4. 4 Kaplowitz, N., Idiosyncratic drug hepatotoxicity. Nat. Rev. Drug Discov. 4 (2005), 489–499.
5. 5 Olson, H., et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 32 (2000), 56–67.
6. 6 Khetani, S.R., et al. Microengineered liver tissues for drug testing. J. Lab. Autom. 20 (2015), 216–250.
7. 7 Lin, C., et al. The application of engineered liver tissues for novel drug discovery. Expert Opin. Drug Discov. 10 (2015), 519–540.
8. 8 Xu, J.J., et al. Cellular imaging predictions of clinical drug-induced liver injury. Toxicol. Sci. 105 (2008), 97–105.
9. 9 Huh, D., et al. From 3D cell culture to organs-on-chips. Trends Cell Biol. 21 (2011), 745–754.
10. 10 Wilkening, S., et al. Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties. Drug Metab. Dispos. 31 (2003), 1035–1042.
11. 11 Kwon, S.J., et al. High-throughput and combinatorial gene expression on a chip for metabolism-induced toxicology screening. Nat. Commun., 5, 2014, 3739.
12. 12 Lee, D.W., et al. Application of the DataChip/MetaChip technology for the evaluation of ajoene toxicity in vitro. Arch. Toxicol. 88 (2014), 283–290.
13. 13 Messner, S., et al. Multi-cell type human liver microtissues for hepatotoxicity testing. Arch. Toxicol. 87 (2013), 209–213.
14. 14 Miyamoto, Y., et al. Spheroid formation and evaluation of hepatic cells in a three-dimensional culture device. Cell Med. 8 (2015), 47–56.
15. 15 Fukuda, J., Nakazawa, K., Hepatocyte spheroid arrays inside microwells connected with microchannels. Biomicrofluidics, 5, 2011, 22205.
16. 16 Trask, O.J. Jr., et al. A micropatterned hepatocyte coculture model for assessment of liver toxicity using high-content imaging analysis. Assay Drug Dev. Technol. 12 (2014), 16–27.
17. 17 Khetani, S.R., Bhatia, S.N., Microscale culture of human liver cells for drug development. Nat. Biotechnol. 26 (2008), 120–126.
18. 18 Wang, W.W., et al. Assessment of a micropatterned hepatocyte coculture system to generate major human excretory and circulating drug metabolites. Drug Metab. Dispos. 38 (2010), 1900–1905.
19. 19 Lin, C., et al. Prediction of drug clearance and drug–drug interactions in microscale cultures of human hepatocytes. Drug Metab. Dispos. 44 (2016), 127–136.
20. 20 Prueksaritanont, T., et al. Drug–drug interaction studies: regulatory guidance and an industry perspective. AAPS J. 15 (2013), 629–645.
21. 21 Khetani, S.R., et al. Use of micropatterned cocultures to detect compounds that cause drug-induced liver injury in humans. Toxicol. Sci. 132 (2013), 107–117.
22. 22 Shlomai, A., et al. Modeling host interactions with hepatitis B virus using primary and induced pluripotent stem cell-derived hepatocellular systems. Proc. Natl. Acad. Sci. 111 (2014), 12193–12198.
23. 23 Ploss, A., et al. Persistent hepatitis C virus infection in microscale primary human hepatocyte cultures. Proc. Natl. Acad. Sci. U.S.A. 107 (2010), 3141–3145.
24. 24 March, S., et al. A microscale human liver platform that supports the hepatic stages of Plasmodium falciparum and vivax. Cell Host Microbe 14 (2013), 104–115.
25. 25 Davidson, M.D., et al. Hormone and drug-mediated modulation of glucose metabolism in a microscale model of the human liver. Tissue Eng. Part C Methods 21 (2015), 716–725.
26. 26 Schwartz, R.E., et al. Pluripotent stem cell-derived hepatocyte-like cells. Biotechnol. Adv. 32 (2014), 504–513.
27. 27 Davidson, M.D., et al. Stem cell-derived liver cells for drug testing and disease modeling. Discov. Med. 19 (2015), 349–358.
28. 28 Takayama, K., et al. 3D spheroid culture of hESC/hiPSC-derived hepatocyte-like cells for drug toxicity testing. Biomaterials 34 (2013), 1781–1789.
29. 29 Berger, D.R., et al. Enhancing the functional maturity of induced pluripotent stem cell-derived human hepatocytes by controlled presentation of cell-cell interactions in vitro. Hepatology 61 (2015), 1370–1381.
30. 30 Ware, B.R., et al. Prediction of drug-induced liver injury in micropatterned co-cultures containing iPSC-derived human hepatocytes. Toxicol. Sci. 145 (2015), 252–262.
31. 31 LeCluyse, E.L., et al. Organotypic liver culture models: meeting current challenges in toxicity testing. Crit. Rev. Toxicol. 42 (2012), 501–548.
32. 32 Nguyen, T.V., et al. Establishment of a hepatocyte–Kupffer cell coculture model for assessment of proinflammatory cytokine effects on metabolizing enzymes and drug transporters. Drug Metab. Dispos. 43 (2015), 774–785.
33. 33 Kostadinova, R., et al. A long-term three dimensional liver co-culture system for improved prediction of clinically relevant drug-induced hepatotoxicity. Toxicol. Appl. Pharmacol. 268 (2013), 1–16.
34. 34 Ma, X., et al. Deterministically patterned biomimetic human iPSC-derived hepatic model via rapid 3D bioprinting. Proc. Natl. Acad. Sci. U.S.A. 113 (2016), 2206–2211.
35. 35 Sivaraman, A., et al. A microscale in vitro physiological model of the liver: predictive screens for drug metabolism and enzyme induction. Curr. Drug Metab. 6 (2005), 569–591.
36. 36 Domansky, K., et al. Perfused multiwell plate for 3D liver tissue engineering. Lab Chip 10 (2010), 51–58.
37. 37 Toh, Y.-C., et al. A microfluidic 3D hepatocyte chip for drug toxicity testing. Lab Chip 9 (2009), 2026–2035.
38. 38 Shih, M.-C., et al. A microfluidic device mimicking acinar concentration gradients across the liver acinus. Biomed. Microdevices 15 (2013), 767–780.
39. 39 Legendre, A., et al. Metabolic characterization of primary rat hepatocytes cultivated in parallel microfluidic biochips. J. Pharm. Sci. 102 (2013), 3264–3276.
40. 40 Baudoin, R., et al. Evaluation of a liver microfluidic biochip to predict in vivo clearances of seven drugs in rats. J. Pharm. Sci. 103 (2014), 706–718.
41. 41 Prot, J.M., et al. A cocktail of metabolic probes demonstrates the relevance of primary human hepatocyte cultures in a microfluidic biochip for pharmaceutical drug screening. Int. J. Pharm. 408 (2011), 67–75.
42. 42 Baudoin, R., et al. Evaluation of seven drug metabolisms and clearances by cryopreserved human primary hepatocytes cultivated in microfluidic biochips. Xenobiotica 43 (2013), 140–152.
43. 43 Leclerc, E., et al. Integration of pharmacokinetic and NRF2 system biology models to describe reactive oxygen species production and subsequent glutathione depletion in liver microfluidic biochips after flutamide exposure. Toxicol. In Vitro 28 (2014), 1230–1241.
44. 44 Choucha-Snouber, L., et al. Metabolomics-on-a-chip of hepatotoxicity induced by anticancer drug flutamide and its active metabolite hydroxyflutamide using HepG2/C3a microfluidic biochips. Toxicol. Sci. 132 (2013), 8–20.
45. 45 Chao, P., et al. Evaluation of a microfluidic based cell culture platform with primary human hepatocytes for the prediction of hepatic clearance in human. Biochem. Pharmacol. 78 (2009), 625–632.
46. 46 Novik, E., et al. A microfluidic hepatic coculture platform for cell-based drug metabolism studies. Biochem. Pharmacol. 79 (2010), 1036–1044.
47. 47 Kim, J.-Y., et al. 96-well format-based microfluidic platform for parallel interconnection of multiple multicellular spheroids. J. Lab. Autom. 20 (2015), 274–282.
48. 48 Frey, O., et al. Reconfigurable microfluidic hanging drop network for multi-tissue interaction and analysis. Nat. Commun., 5, 2014, 4250.
49. 49 Kang, Y.B.A., et al. Liver sinusoid on a chip: long-term layered co-culture of primary rat hepatocytes and endothelial cells in microfluidic platforms. Biotechnol. Bioeng. 112 (2015), 2571–2582.
50. 50 Kasuya, J., et al. Spatio-temporal control of hepatic stellate cell-endothelial cell interactions for reconstruction of liver sinusoids in vitro. Tissue Eng. Part A 18 (2012), 1045–1056.
51. 51 Vernetti, L.A., et al. A human liver microphysiology platform for investigating physiology, drug safety, and disease models. Exp. Biol. Med. 241 (2016), 101–114.
52. 52 Prodanov, L., et al. Long-term maintenance of a microfluidic 3D human liver sinusoid. Biotechnol. Bioeng. 113 (2016), 241–246.
53. 53 Lee, P.J., et al. An artificial liver sinusoid with a microfluidic endothelial-like barrier for primary hepatocyte culture. Biotechnol. Bioeng. 97 (2007), 1340–1346.
54. 54 Nakao, Y., et al. Bile canaliculi formation by aligning rat primary hepatocytes in a microfluidic device. Biomicrofluidics, 5, 2011, 22212.
55. 55 Kmieć, Z., Cooperation of liver cells in health and disease. Adv. Anat. Embryol. Cell Biol. 161 (2001), 1–151.
56. 56 Bavli, D., et al. Real-time monitoring of metabolic function in liver-on-chip microdevices tracks the dynamics of mitochondrial dysfunction. Proc. Natl. Acad. Sci. U.S.A. 113 (2016), E2231–E2240.
57. 57 Rennert, K., et al. A microfluidically perfused three dimensional human liver model. Biomaterials 71 (2015), 119–131.
58. 58 Matharu, Z., et al. Detecting transforming growth factor-β release from liver cells using an aptasensor integrated with microfluidics. Anal. Chem. 86 (2014), 8865–8872.
59. 59 Zhou, Q., et al. Liver injury-on-a-chip: microfluidic co-cultures with integrated biosensors for monitoring liver cell signaling during injury. Lab Chip 15 (2015), 4467–4478.
60. 60 Anundi, I., et al. Zonation of acetaminophen metabolism and cytochrome P450 2E1-mediated toxicity studied in isolated periportal and perivenous hepatocytes. Biochem. Pharmacol. 45 (1993), 1251–1259.
61. 61 Allen, J.W., et al. In vitro zonation and toxicity in a hepatocyte bioreactor. Toxicol. Sci. 84 (2005), 110–119.
62. 62 Sato, A., et al. An in vitro hepatic zonation model with a continuous oxygen gradient in a microdevice. Biochem. Biophys. Res. Commun. 453 (2014), 767–771.
63. 63 Peng, C.-C., et al. A microfluidic cell culture array with various oxygen tensions. Lab Chip 13 (2013), 3239–3245.
64. 64 Viravaidya, K., et al. Development of a microscale cell culture analog to probe naphthalene toxicity. Biotechnol. Prog. 20 (2004), 316–323.
65. 65 Esch, M.B., et al. Body-on-a-chip simulation with gastrointestinal tract and liver tissues suggests that ingested nanoparticles have the potential to cause liver injury. Lab Chip 14 (2014), 3081–3092.
66. 66 Bricks, T., et al. Development of a new microfluidic platform integrating co-cultures of intestinal and liver cell lines. Toxicol. In Vitro 28 (2014), 885–895.
67. 67 Choucha-Snouber, L., et al. Investigation of ifosfamide nephrotoxicity induced in a liver-kidney co-culture biochip. Biotechnol. Bioeng. 110 (2013), 597–608.
68. 68 Materne, E.-M., et al. A multi-organ chip co-culture of neurospheres and liver equivalents for long-term substance testing. J. Biotechnol. 205 (2015), 36–46.
69. 69 Zervantonakis, I.K., et al. Three-dimensional microfluidic model for tumor cell intravasation and endothelial barrier function. Proc. Natl. Acad. Sci. U.S.A. 109 (2012), 13515–13520.
70. 70 Wagner, I., et al. A dynamic multi-organ-chip for long-term cultivation and substance testing proven by 3D human liver and skin tissue co-culture. Lab Chip 13 (2013), 3538–3547.
71. 71 Materne, E.-M., et al. The multi-organ chip – a microfluidic platform for long-term multi-tissue coculture. J. Vis. Exp., 98, 2015, 52526.
72. 72 Kimura, H., et al. An on-chip small intestine-liver model for pharmacokinetic studies. J. Lab. Autom. 20 (2015), 265–273.
73. 73 Sung, J.H., et al. A microfluidic device for a pharmacokinetic-pharmacodynamic (PK-PD) model on a chip. Lab Chip 10 (2010), 446–455.
74. 74 Maschmeyer, I., et al. A four-organ-chip for interconnected long-term co-culture of human intestine, liver, skin and kidney equivalents. Lab Chip 15 (2015), 2688–2699.
75. 75 Oleaga, C., et al. Multi-Organ toxicity demonstration in a functional human in vitro system composed of four organs. Sci. Rep., 6, 2016, 20030.